Thomas Gerard Cotter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Gerard Cotter has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Michael Charlton
Transplant Institute, Center for Liver Diseases, University of Chicago Biological Sciences, Chicago, USA
8 shared publications Ahmad Anouti
Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX, USA
5 shared publications- Ahmad Anouti
Department of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA
5 shared publications Amit G. Singal
Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX
5 shared publicationsMack C. Mitchell
Division of Digestive and Liver Diseases UT Southwestern Medical Center Dallas Texas USA
5 shared publicationsBurhaneddin Sandıkçı
Booth School of Business, The University of Chicago, Chicago, IL, USA
4 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 54
Prognostic biomarkers in Fontan associated liver disease
Fontan-associated liver disease (FALD) is a universal consequence of the Fontan circulation and a growing cause of morbidity. Clinical outcome stratification is difficult because conventional tests lack sensitivity. In this review, we aim to discuss current prognostic tools for FALD. Histology remains the reference standard, capturing the characteristic pericentral and bridging “reverse lobulation” pattern of fibrosis. However, the invasive nature of liver biopsy and susceptibility to sampling bias limit its use. Magnetic resonance elastography (MRE) provides whole-organ stiffness assessment with concurrent evaluation of splenomegaly and varices, yet stiffness thresholds are not standardized and may overestimate fibrosis in the setting of hepatic congestion. Serum and composite indices [e.g., aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI)] provide some limited prognostic information in FALD; however, there is a need for disease-specific models. Emerging work integrates imaging and laboratory data to build risk calculators such as the FALD and Fontan Liver Risk Score (FonLiver). Multicenter pediatric validation and outcome-based calibration remain major gaps. Future progress requires prospective, multicenter pediatric studies with harmonized imaging protocols and novel biomarkers. Such integration is essential to move FALD prognostication from descriptive observation toward predictive and ultimately preventative care, optimizing timing of intervention and associated transplant decisions for individuals living with Fontan circulation.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 54
Open AccessPrognostic biomarkers in Fontan associated liver disease
Fontan-associated liver disease (FALD) is a universal consequence of the Fontan circulation and a growing cause of morbidity. Clinical outcome stratification is difficult because conventional tests lack sensitivity. In this review, we aim to discuss current prognostic tools for FALD. Histology remains the reference standard, capturing the characteristic pericentral and bridging “reverse lobulation” pattern of fibrosis. However, the invasive nature of liver biopsy and susceptibility to sampling bias limit its use. Magnetic resonance elastography (MRE) provides whole-organ stiffness assessment with concurrent evaluation of splenomegaly and varices, yet stiffness thresholds are not standardized and may overestimate fibrosis in the setting of hepatic congestion. Serum and composite indices [e.g., aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI)] provide some limited prognostic information in FALD; however, there is a need for disease-specific models. Emerging work integrates imaging and laboratory data to build risk calculators such as the FALD and Fontan Liver Risk Score (FonLiver). Multicenter pediatric validation and outcome-based calibration remain major gaps. Future progress requires prospective, multicenter pediatric studies with harmonized imaging protocols and novel biomarkers. Such integration is essential to move FALD prognostication from descriptive observation toward predictive and ultimately preventative care, optimizing timing of intervention and associated transplant decisions for individuals living with Fontan circulation.
- Open Access
- 22 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70489
Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials
Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.
- 22 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70489
Open AccessIntegrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials
Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.
- Open Access
- 5 July 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (11) , 2410-2423
The current state of simultaneous heart-liver transplantation in the United States
- 5 July 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (11) , 2410-2423
Open AccessThe current state of simultaneous heart-liver transplantation in the United States
- 22 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1836-1837
Letter: Addressing the Growing Disparities in Alcohol‐Associated Liver Disease—A Call for Equitable Healthcare Strategies: Authors' Reply
- 22 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1836-1837
Letter: Addressing the Growing Disparities in Alcohol‐Associated Liver Disease—A Call for Equitable Healthcare Strategies: Authors' Reply
- 18 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (1) , 182-191
Current Clinical Trials for Alcohol-Associated Hepatitis
- 18 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (1) , 182-191
Current Clinical Trials for Alcohol-Associated Hepatitis
- 30 January 2025
- Published by Elsevier in Clinics in Liver Disease
- Vol. 29 (2) , 165-184
Liver Transplantation in Alcohol-Associated Liver Disease
- 30 January 2025
- Published by Elsevier in Clinics in Liver Disease
- Vol. 29 (2) , 165-184
Liver Transplantation in Alcohol-Associated Liver Disease
- Open Access
- 16 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (6) , 988-999
Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
Introduction: Alcohol‐associated liver disease (ALD) disproportionately impacts men, racial and ethnic minorities, and individuals of low socioeconomic status; however, it's unclear how recent increases in ALD burden have impacted these disparities. We aimed to describe trends in racial, ethnic and socioeconomic disparities in alcohol‐associated hospital encounters.Methods: We conducted a retrospective cohort study of adult hospital encounters with alcohol‐associated diagnoses from three health systems between January 2016 and December 2021. The cohort was divided into three eras: a ‘Historical Era,’ (Oct 2016—June 2018, used only for trends); ‘Era 1’ (July 2018—March 2020); and ‘Era 2’ (April 2020—December 2021). Kaplan Meier and Cox regression analyses were performed to identify factors associated with overall survival.Results: We identified 19,295 individuals with alcohol‐associated encounters (44.7% White, 29.8% Hispanic, and 21.8% non‐Hispanic Black (NHB) individuals), with a greater increase observed between eras 1 and 2 than the historical era and Era 1 (8.7% vs. 5.0%, p < 0.01). By age and sex, the greatest increases in encounters were observed in the youngest and oldest females but only the oldest males. By race and ethnicity, Hispanic individuals had greater increases in encounters compared to Black and White individuals (14.8% vs. 7.5% and 6.3%, p < 0.01). Older age (aSHR: 1.03, 95% CI: 1.03–1.0), higher MELD (aSHR: 1.08, 95% CI: 1.0–1.09), hepatic encephalopathy (aSHR: 1.42, 95% CI: 1.06–1.90), and hepatocellular carcinoma (HCC) (aSHR: 3.20, 95% CI: 2.29–4.49) were associated with increased mortality.Conclusion: The highest increases of alcohol‐associated encounters were observed amongst young Hispanic and NHB women, highlighting variation in trends by age, sex, race and ethnicity. These disparities merit further investigation to elucidate underlying mechanisms and develop tailored interventions to improve ALD burden and outcomes.
- 16 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (6) , 988-999
Open AccessDisparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
Introduction: Alcohol‐associated liver disease (ALD) disproportionately impacts men, racial and ethnic minorities, and individuals of low socioeconomic status; however, it's unclear how recent increases in ALD burden have impacted these disparities. We aimed to describe trends in racial, ethnic and socioeconomic disparities in alcohol‐associated hospital encounters.Methods: We conducted a retrospective cohort study of adult hospital encounters with alcohol‐associated diagnoses from three health systems between January 2016 and December 2021. The cohort was divided into three eras: a ‘Historical Era,’ (Oct 2016—June 2018, used only for trends); ‘Era 1’ (July 2018—March 2020); and ‘Era 2’ (April 2020—December 2021). Kaplan Meier and Cox regression analyses were performed to identify factors associated with overall survival.Results: We identified 19,295 individuals with alcohol‐associated encounters (44.7% White, 29.8% Hispanic, and 21.8% non‐Hispanic Black (NHB) individuals), with a greater increase observed between eras 1 and 2 than the historical era and Era 1 (8.7% vs. 5.0%, p < 0.01). By age and sex, the greatest increases in encounters were observed in the youngest and oldest females but only the oldest males. By race and ethnicity, Hispanic individuals had greater increases in encounters compared to Black and White individuals (14.8% vs. 7.5% and 6.3%, p < 0.01). Older age (aSHR: 1.03, 95% CI: 1.03–1.0), higher MELD (aSHR: 1.08, 95% CI: 1.0–1.09), hepatic encephalopathy (aSHR: 1.42, 95% CI: 1.06–1.90), and hepatocellular carcinoma (HCC) (aSHR: 3.20, 95% CI: 2.29–4.49) were associated with increased mortality.Conclusion: The highest increases of alcohol‐associated encounters were observed amongst young Hispanic and NHB women, highlighting variation in trends by age, sex, race and ethnicity. These disparities merit further investigation to elucidate underlying mechanisms and develop tailored interventions to improve ALD burden and outcomes.
- Open Access
- 18 September 2024
- Published by MDPI AG in Preprints.org
Racial, Ethnic, and Socioeconomic Disparities in Access to Critical Procedures in Patients Hospitalized with Cirrhosis Complications
Cirrhosis is a critical global health issue, responsible for 2.4% of deaths worldwide in 2019. The Global Burden of Disease Study reported a near doubling of decompensated cirrhosis cases from 1990 to 2017. In the U.S., cirrhosis is the 12th leading cause of death and often requires hospitali-zation and procedural interventions for severe complications such as hepatocellular carcinoma, ascites, hepatic encephalopathy, and variceal bleeding. This study aims to identify racial, ethnic, and socioeconomic disparities in receiving critical interventions among U.S. patients with de-compensated cirrhosis during 2020-2021. We conducted a retrospective cross-sectional analysis using 2020-2021 National Inpatient Sample data of adult patients (≥18 years) with cirrhosis-related and cirrhosis complication-related ICD-10 codes and who underwent procedures for cirrhosis-related indications such as esophagogastroduodenoscopy (EGD) for variceal hemor-rhage, transjugular intrahepatic portosystemic shunt (TIPS) for variceal hemorrhage or refractory ascites, hemodialysis for acute kidney failure or hepatorenal syndrome, and liver transplantation We collected data on patient baseline clinicodemographic and procedural outcomes. Statistical analyses included multivariable logistic regression to assess for associations with outcomes. There were significant disparities in procedure utilization: White and Hispanic patients more likely than Black patients to receive EGD and TIPS, while Black and Hispanic patients had higher odds of receiving hemodialysis. Insurance type also influenced access, with Private/HMO insurance holders having higher odds of undergoing procedures. These findings underscore the need for targeted interventions to address healthcare inequities.
- 18 September 2024
- Published by MDPI AG in Preprints.org
Open AccessRacial, Ethnic, and Socioeconomic Disparities in Access to Critical Procedures in Patients Hospitalized with Cirrhosis Complications
Cirrhosis is a critical global health issue, responsible for 2.4% of deaths worldwide in 2019. The Global Burden of Disease Study reported a near doubling of decompensated cirrhosis cases from 1990 to 2017. In the U.S., cirrhosis is the 12th leading cause of death and often requires hospitali-zation and procedural interventions for severe complications such as hepatocellular carcinoma, ascites, hepatic encephalopathy, and variceal bleeding. This study aims to identify racial, ethnic, and socioeconomic disparities in receiving critical interventions among U.S. patients with de-compensated cirrhosis during 2020-2021. We conducted a retrospective cross-sectional analysis using 2020-2021 National Inpatient Sample data of adult patients (≥18 years) with cirrhosis-related and cirrhosis complication-related ICD-10 codes and who underwent procedures for cirrhosis-related indications such as esophagogastroduodenoscopy (EGD) for variceal hemor-rhage, transjugular intrahepatic portosystemic shunt (TIPS) for variceal hemorrhage or refractory ascites, hemodialysis for acute kidney failure or hepatorenal syndrome, and liver transplantation We collected data on patient baseline clinicodemographic and procedural outcomes. Statistical analyses included multivariable logistic regression to assess for associations with outcomes. There were significant disparities in procedure utilization: White and Hispanic patients more likely than Black patients to receive EGD and TIPS, while Black and Hispanic patients had higher odds of receiving hemodialysis. Insurance type also influenced access, with Private/HMO insurance holders having higher odds of undergoing procedures. These findings underscore the need for targeted interventions to address healthcare inequities.
- Open Access
- 3 August 2024
- Published by Wiley in Liver International
- Vol. 44 (10) , 2822-2833
Racial and ethnic disparities in the natural history of alcohol‐associated liver disease in the United States
Background: Outcomes in alcohol‐associated liver disease (ALD) are influenced by several race and ethnic factors, yet its natural history across the continuum of patients in different stages of the disease is unknown.Methods: We conducted a retrospective cohort study of U.S. adults from 2011 to 2018, using three nationally representative databases to examine potential disparities in relevant outcomes among racial and ethnic groups. Our analysis included logistic and linear regressions, along with competing risk analysis.Results: Black individuals had the highest daily alcohol consumption (12.6 g/day) while Hispanic participants had the largest prevalence of heavy episodic drinking (33.5%). In a multivariable‐adjusted model, Hispanic and Asian participants were independently associated with a higher ALD prevalence compared to Non‐Hispanic White interviewees (OR: 1.4, 95% CI: 1.1–1.8 and OR: 1.5 95% CI:1.1–2.0, respectively), while Blacks participants had a lower ALD prevalence (OR: .7 95% CI: .6–.9), and a lower risk of mortality during hospitalization due to ALD (OR: .83 95% CI: .73–.94). Finally, a multivariate competing‐risk analysis showed that Hispanic ethnicity had a decreased probability of liver transplantation if waitlisted for ALD (SHR: .7, 95% CI: .6–.8) along with female Asian population (HR: .40, 95% CI: .26–.62).Conclusions: After accounting for key social and biological health determinants, the Hispanic population showed an increased risk of ALD prevalence, even with lower alcohol consumption. Additionally, Hispanic and Asian female patients had reduced access to liver transplantation compared to other enlisted patients.
- 3 August 2024
- Published by Wiley in Liver International
- Vol. 44 (10) , 2822-2833
Open AccessRacial and ethnic disparities in the natural history of alcohol‐associated liver disease in the United States
Background: Outcomes in alcohol‐associated liver disease (ALD) are influenced by several race and ethnic factors, yet its natural history across the continuum of patients in different stages of the disease is unknown.Methods: We conducted a retrospective cohort study of U.S. adults from 2011 to 2018, using three nationally representative databases to examine potential disparities in relevant outcomes among racial and ethnic groups. Our analysis included logistic and linear regressions, along with competing risk analysis.Results: Black individuals had the highest daily alcohol consumption (12.6 g/day) while Hispanic participants had the largest prevalence of heavy episodic drinking (33.5%). In a multivariable‐adjusted model, Hispanic and Asian participants were independently associated with a higher ALD prevalence compared to Non‐Hispanic White interviewees (OR: 1.4, 95% CI: 1.1–1.8 and OR: 1.5 95% CI:1.1–2.0, respectively), while Blacks participants had a lower ALD prevalence (OR: .7 95% CI: .6–.9), and a lower risk of mortality during hospitalization due to ALD (OR: .83 95% CI: .73–.94). Finally, a multivariate competing‐risk analysis showed that Hispanic ethnicity had a decreased probability of liver transplantation if waitlisted for ALD (SHR: .7, 95% CI: .6–.8) along with female Asian population (HR: .40, 95% CI: .26–.62).Conclusions: After accounting for key social and biological health determinants, the Hispanic population showed an increased risk of ALD prevalence, even with lower alcohol consumption. Additionally, Hispanic and Asian female patients had reduced access to liver transplantation compared to other enlisted patients.
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Brief alcohol interventions are underutilized in persons with nonalcohol-associated chronic liver diseases
Background: Brief alcohol interventions use patient-provider communication to promote alcohol cessation. We characterized the receipt of this intervention in chronic liver disease (CLD). Methods: We surveyed patients with CLD for weekly drinking patterns and examined associations with patient-provider communication receipt. Results: Among 840 participants, 82.1% and 56.5% reported ≥1 standard drink weekly and excessive alcohol consumption, respectively. Patient-provider communication was lower in noncirrhotic (adjusted odds ratio:0.34, 95% CI: 0.22–0.54) and nonalcohol-associated CLD (adjusted odds ratio: 0.22, 95% CI: 0.15–0.34) among individuals drinking ≥1 standard drink weekly, and similarly in noncirrhotic CLD (adjusted odds ratio: 0.45, 95% CI: 0.21–0.95) among those with excessive drinking. Conclusions: Brief alcohol interventions are underutilized in noncirrhotic and nonalcohol-associated CLD.
- 1 April 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Open AccessBrief alcohol interventions are underutilized in persons with nonalcohol-associated chronic liver diseases
Background: Brief alcohol interventions use patient-provider communication to promote alcohol cessation. We characterized the receipt of this intervention in chronic liver disease (CLD). Methods: We surveyed patients with CLD for weekly drinking patterns and examined associations with patient-provider communication receipt. Results: Among 840 participants, 82.1% and 56.5% reported ≥1 standard drink weekly and excessive alcohol consumption, respectively. Patient-provider communication was lower in noncirrhotic (adjusted odds ratio:0.34, 95% CI: 0.22–0.54) and nonalcohol-associated CLD (adjusted odds ratio: 0.22, 95% CI: 0.15–0.34) among individuals drinking ≥1 standard drink weekly, and similarly in noncirrhotic CLD (adjusted odds ratio: 0.45, 95% CI: 0.21–0.95) among those with excessive drinking. Conclusions: Brief alcohol interventions are underutilized in noncirrhotic and nonalcohol-associated CLD.